Rise in prevalence of rare diseases is one of the prominent factors augmenting the global orphan drugs market growth. Orphan pharmaceuticals are developed in order to treat rare ‘orphan’ diseases.
Increase in percentage of population suffering from such rare diseases is another factor driving market development. To date, nearly 600 orphan drugs have been approved by regulatory bodies such as the U.S. FDA.
Recognizing the need for sustained research and development efforts, companies operating in the global orphan drugs market are engaged in providing timely, equitable, and sustainable access to rare disease therapeutics.
They are embracing rapidly advancing science and changing treatment paradigms to carry out innovations in orphan disease and orphan medicine development.
Orphan drugs, also known as rare disorder medications, are drugs that are developed for the treatment of certain rare medical conditions.
Assigning the status of ‘orphan disease’ is at the discretion of a country. In other words, the legislations passed by a country decide if a particular disease should be categorized as ‘orphan.’
Neurological disorders constitute more than 50% of rare diseases. Rare central nervous system (CNS) disorders are challenging to diagnose, due to a dearth of diagnostic genomic sequencing and clinical expertise.
Some of these disorders include reflex sympathetic dystrophy syndrome, Creutzfeldt Jakob Disease, Battaglia-Neri syndrome, Aicardi Syndrome, Agnosia, and Aicardi-Goutieres syndrome.
As per the National Organization for Rare Disorders (NORD), there are over 7,000 rare diseases affecting almost 30 million Americans. Furthermore, according to data published by Center for Rare Neurological Disease Research in January 2021, nearly 20,000 individuals were afflicted with rare neurological diseases in the U.S.
Emergence of several rare diseases and approval of certain orphan drugs, especially those related to cancer, by the U.S. FDA are fueling the orphan drugs market size.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
The last three decades have witnessed a marked revolution in genomics, which is an outcome of bigger strides in research pertaining to rare diseases. Around 6,000 to 8,000 unique rare diseases have been identified as of now, with 80% being genetic and 50%-75% categorized as pediatric onset.
Orphan diseases are termed as rare; however, collective number of people adversely affected by these rare diseases is quite large.
Prolonged diagnostic odyssey, lack of monetary compensation, and lifelong disabilities are the unmet needs plaguing the lives of patients suffering from rare disorders.
As per the National Institute of Health, 25% of patients affected by rare diseases receive multiple misdiagnoses, which results in ineffective medical management. It further states that patients in the U.S. visit eight physicians and receive two to three misdiagnoses.
Thus, increase in incidence of rare diseases and need for precise treatment regimen are creating lucrative orphan drugs market opportunities for companies operating in the global landscape.
The latest orphan drugs market trends indicate creation of a supportive policy framework for research, development, and commercialization; and introduction of customized approaches that meet the needs of the healthcare system and patients.
Growth in understanding and awareness about orphan diseases has prompted several established players and biopharmaceutical companies to create robust pipeline candidates for orphan drugs.
In 2021, more than 50% of the U.S. FDA’s Center for Drug Evaluation and Research’s (CDER’s) approvals comprised orphan designation. The Center for Biologics Evaluation and Research (CBER) approved two CAR-T cell therapies.
In May 2020, Daiichi Sankyo Company and AstraZeneca Plc received orphan drug designation from the U.S. FDA for Enhertu (Trastuzumab deruxtecan) to treat patients contracting gastric cancer.
In June 2020, Agios Pharmaceuticals, Inc. received orphan drug designation from the U.S. FDA for Mitapivat, its pipeline candidate for the treatment of thalassemia.
In November 2021, PharmaTher Holdings Ltd. received orphan drug designation from the U.S. FDA to treat Status Epilepticus, one of the rarest neurological disorders. Thus, rise in R&D activities is accelerating the orphan drugs market.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest orphan drugs market analysis, North America accounted for the largest share in terms of demand for orphan pharmaceuticals in 2023. The region is expected to continue with its dominance during the forecast period.
The U.S. follows the practice of according seven years of marketing exclusivity to a drug designated as orphan drug post the U.S. FDA’s approval regarding free waiver and tax credits.
Increase in number of orphan drugs introduced to treat rare cancers is also boosting the orphan drugs market share of North America.
In February 2022, CTI BioPharma received approval from the U.S. FDA for Pacritinib to treat adult patients suffering from Myelofibrosis, a rare bone cancer that affects more than 21,000 people in the U.S. every year.
Companies operating in the global orphan drugs industry are launching new orphan drugs. In March 2022, Marinus Pharmaceuticals received approval from the U.S. FDA for ZTALMY (ganaxolone) to treat seizures linked with rare cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged two and above.
Novartis AG, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Sanofi S.A., Alexion Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, AstraZeneca plc, Eisai Co., Ltd., Daiichi Sankyo Company Limited, Bayer AG, GlaxoSmithKline plc, Merck & Co., Inc., Johnson & Johnson, Biogen, Inc., Shire plc, and Amgen, Inc. are the leading players covered in the orphan drugs market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 195.0 Bn |
| Market Forecast (Value) in 2034 | US$ 424.0 Bn |
| Growth Rate (CAGR) | 6.9% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 195.0 Bn in 2023
It is projected to grow at a CAGR of 6.9% from 2024 to 2034
Growth in prevalence of rare diseases and misdiagnosis of such diseases, and increase in R&D activities
The hospital pharmacies segment accounted for the largest share in 2023
North America was the dominant region in in 2023
Novartis AG, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Sanofi S.A., Alexion Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, AstraZeneca plc, Eisai Co., Ltd., Daiichi Sankyo Company Limited, Bayer AG, GlaxoSmithKline plc, Merck & Co., Inc., Johnson & Johnson, Biogen, Inc., Shire plc, and Amgen, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Orphan Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Orphan Drugs Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Orphan Drugs Market Analysis and Forecast, by Disease Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease Type, 2020-2034
6.3.1. Oncology
6.3.2. Gastrointestinal
6.3.3. Pulmonary
6.3.4. Neurology
6.3.5. Hematology
6.3.6. Cardiovascular
6.3.7. Metabolic Disorders
6.3.8. Endocrinology
6.3.9. Infectious Diseases
6.3.10. Others
6.4. Market Attractiveness, by Disease Type
7. Global Orphan Drugs Market Analysis and Forecast, by Indicator
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indicator, 2020-2034
7.3.1. Biologic
7.3.2. Non-biologic
7.4. Market Attractiveness, by Indicator
8. Global Orphan Drugs Market Analysis and Forecast, By Distribution Channel
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, By Distribution Channel, 2020-2034
8.3.1. Hospital Pharmacies
8.3.2. Specialty Pharmacies
8.3.3. Retail Pharmacies
8.3.4. Others
8.4. Market Attractiveness, By Distribution Channel
9. Global Orphan Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Orphan Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Disease Type, 2020-2034
10.2.1. Oncology
10.2.2. Gastrointestinal
10.2.3. Pulmonary
10.2.4. Neurology
10.2.5. Hematology
10.2.6. Cardiovascular
10.2.7. Metabolic Disorders
10.2.8. Endocrinology
10.2.9. Infectious Diseases
10.2.10. Others
10.3. Market Attractiveness, by Disease Type
10.4. Market Value Forecast, by Indicator, 2020-2034
10.4.1. Biologic
10.4.2. Non-biologic
10.5. Market Attractiveness, by Indicator
10.6. Market Value Forecast, By Distribution Channel, 2020-2034
10.6.1. Hospital Pharmacies
10.6.2. Specialty Pharmacies
10.6.3. Retail Pharmacies
10.6.4. Others
10.7. Market Attractiveness, By Distribution Channel
10.8. Market Value Forecast, by Country/Sub-region, 2020-2034
10.8.1. U.S.
10.8.2. Canada
10.9. Market Attractiveness Analysis
10.9.1. By Disease Type
10.9.2. By Indicator
10.9.3. By Distribution Channel
10.9.4. By Country
11. Europe Orphan Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Disease Type, 2020-2034
11.2.1. Oncology
11.2.2. Gastrointestinal
11.2.3. Pulmonary
11.2.4. Neurology
11.2.5. Hematology
11.2.6. Cardiovascular
11.2.7. Metabolic Disorders
11.2.8. Endocrinology
11.2.9. Infectious Diseases
11.2.10. Others
11.3. Market Attractiveness, by Disease Type
11.4. Market Value Forecast, by Indicator, 2020-2034
11.4.1. Biologic
11.4.2. Non-biologic
11.5. Market Attractiveness, by Indicator
11.6. Market Value Forecast, By Distribution Channel, 2020-2034
11.6.1. Hospital Pharmacies
11.6.2. Specialty Pharmacies
11.6.3. Retail Pharmacies
11.6.4. Others
11.7. Market Attractiveness, By Distribution Channel
11.8. Market Value Forecast, by Country/Sub-region, 2020-2034
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Market Attractiveness Analysis
11.9.1. By Disease Type
11.9.2. By Indicator
11.9.3. By Distribution Channel
11.9.4. By Country/Sub-region
12. Asia Pacific Orphan Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Disease Type, 2020-2034
12.2.1. Oncology
12.2.2. Gastrointestinal
12.2.3. Pulmonary
12.2.4. Neurology
12.2.5. Hematology
12.2.6. Cardiovascular
12.2.7. Metabolic Disorders
12.2.8. Endocrinology
12.2.9. Infectious Diseases
12.2.10. Others
12.3. Market Attractiveness, by Disease Type
12.4. Market Value Forecast, by Indicator, 2020-2034
12.4.1. Biologic
12.4.2. Non-biologic
12.5. Market Attractiveness, by Indicator
12.6. Market Value Forecast, By Distribution Channel, 2020-2034
12.6.1. Hospital Pharmacies
12.6.2. Specialty Pharmacies
12.6.3. Retail Pharmacies
12.6.4. Others
12.7. Market Attractiveness, By Distribution Channel
12.8. Market Value Forecast, by Country/Sub-region, 2020-2034
12.8.1. China
12.8.2. Japan
12.8.3. India
12.8.4. Australia & New Zealand
12.8.5. Rest of Asia Pacific
12.9. Market Attractiveness Analysis
12.9.1. By Disease Type
12.9.2. By Indicator
12.9.3. By Distribution Channel
12.9.4. By Country/Sub-region
13. Latin America Orphan Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Disease Type, 2020-2034
13.2.1. Oncology
13.2.2. Gastrointestinal
13.2.3. Pulmonary
13.2.4. Neurology
13.2.5. Hematology
13.2.6. Cardiovascular
13.2.7. Metabolic Disorders
13.2.8. Endocrinology
13.2.9. Infectious Diseases
13.2.10. Others
13.3. Market Attractiveness, by Disease Type
13.4. Market Value Forecast, by Indicator, 2020-2034
13.4.1. Biologic
13.4.2. Non-biologic
13.5. Market Attractiveness, by Indicator
13.6. Market Value Forecast, By Distribution Channel, 2020-2034
13.6.1. Hospital Pharmacies
13.6.2. Specialty Pharmacies
13.6.3. Retail Pharmacies
13.6.4. Others
13.7. Market Attractiveness, By Distribution Channel
13.8. Market Value Forecast, by Country/Sub-region, 2020-2034
13.8.1. Brazil
13.8.2. Mexico
13.8.3. Rest of Latin America
13.9. Market Attractiveness Analysis
13.9.1. By Disease Type
13.9.2. By Indicator
13.9.3. By Distribution Channel
13.9.4. By Country/Sub-region
14. Middle East & Africa Orphan Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Disease Type, 2020-2034
14.2.1. Oncology
14.2.2. Gastrointestinal
14.2.3. Pulmonary
14.2.4. Neurology
14.2.5. Hematology
14.2.6. Cardiovascular
14.2.7. Metabolic Disorders
14.2.8. Endocrinology
14.2.9. Infectious Diseases
14.2.10. Others
14.3. Market Attractiveness, by Disease Type
14.4. Market Value Forecast, by Indicator, 2020-2034
14.4.1. Biologic
14.4.2. Non-biologic
14.5. Market Attractiveness, by Indicator
14.6. Market Value Forecast, By Distribution Channel, 2020-2034
14.6.1. Hospital Pharmacies
14.6.2. Specialty Pharmacies
14.6.3. Retail Pharmacies
14.6.4. Others
14.7. Market Attractiveness, By Distribution Channel
14.8. Market Value Forecast, by Country/Sub-region, 2020-2034
14.8.1. GCC Countries
14.8.2. South Africa
14.8.3. Rest of Middle East & Africa
14.9. Market Attractiveness Analysis
14.9.1. By Disease Type
14.9.2. By Indicator
14.9.3. By Distribution Channel
14.9.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Novartis AG
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Bristol-Myers Squibb Company
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Celgene Corporation
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. F. Hoffmann-La Roche Ltd.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Pfizer, Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Sanofi S.A.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Alexion Pharmaceuticals, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Eli Lilly and Company
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Novo Nordisk A/S
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. AstraZeneca plc
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Eisai Co., Ltd.
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. Daiichi Sankyo Company Limited
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Product Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
15.3.13. Bayer AG
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Product Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.13.5. Strategic Overview
15.3.14. GlaxoSmithKline plc
15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.14.2. Product Portfolio
15.3.14.3. Financial Overview
15.3.14.4. SWOT Analysis
15.3.14.5. Strategic Overview
15.3.15. Merck & Co., Inc.
15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.15.2. Product Portfolio
15.3.15.3. Financial Overview
15.3.15.4. SWOT Analysis
15.3.15.5. Strategic Overview
15.3.16. Johnson & Johnson
15.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.16.2. Product Portfolio
15.3.16.3. Financial Overview
15.3.16.4. SWOT Analysis
15.3.16.5. Strategic Overview
15.3.17. Biogen, Inc.
15.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.17.2. Product Portfolio
15.3.17.3. Financial Overview
15.3.17.4. SWOT Analysis
15.3.17.5. Strategic Overview
15.3.18. Shire plc
15.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.18.2. Product Portfolio
15.3.18.3. Financial Overview
15.3.18.4. SWOT Analysis
15.3.18.5. Strategic Overview
15.3.19. Amgen, Inc.
15.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.19.2. Product Portfolio
15.3.19.3. Financial Overview
15.3.19.4. SWOT Analysis
15.3.19.5. Strategic Overview
List of Tables
Table 01: Global Orphan Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 02: Global Orphan Drugs Market Size (US$ Mn) Forecast, by Indicator, 2020-2034
Table 03: Global Orphan Drugs Market Size (US$ Mn) Forecast, by Region, 2020-2034
Table 04: North America Orphan Drugs Market Size (US$ Mn) Forecast, by Country, 2020-2034
Table 05: North America Orphan Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 06: North America Orphan Drugs Market Size (US$ Mn) Forecast, by Indicator, 2020-2034
Table 07: Europe Orphan Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 08: Europe Orphan Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 09: Europe Orphan Drugs Market Size (US$ Mn) Forecast, by Indicator, 2020-2034
Table 10: Asia Pacific Orphan Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 11: Asia Pacific Orphan Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 12: Asia Pacific Orphan Drugs Market Size (US$ Mn) Forecast, by Indicator, 2020-2034
Table 13: Latin America Orphan Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Latin America Orphan Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 15: Latin America Orphan Drugs Market Size (US$ Mn) Forecast, by Indicator, 2020-2034
Table 16: Middle East & Africa Orphan Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Middle East & Africa Orphan Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 18: Middle East & Africa Orphan Drugs Market Size (US$ Mn) Forecast, by Indicator, 2020-2034
List of Figures
Figure 01: Global Orphan Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Orphan Drugs Market Revenue (US$ Mn), by Disease Type, 2023
Figure 03: Global Orphan Drugs Market Value Share, by Disease Type, 2023
Figure 04: Global Orphan Drugs Market Revenue (US$ Mn), by Indicator, 2023
Figure 05: Global Orphan Drugs Market Value Share, by Indicator, 2023
Figure 06: Global Orphan Drugs Market Revenue (US$ Mn), By Distribution Channel, 2023
Figure 07: Global Orphan Drugs Market Value Share, By Distribution Channel, 2023
Figure 08: Global Orphan Drugs Market Value Share, by Region, 2023
Figure 09: Global Orphan Drugs Market Value (US$ Mn) Forecast, 2020-2034
Figure 10: Global Orphan Drugs Market Value Share Analysis, by Disease Type, 2023 and 2034
Figure 11: Global Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 12: Global Orphan Drugs Market Value Share Analysis, by Indicator, 2023 and 2034
Figure 13: Global Orphan Drugs Market Attractiveness Analysis, by Indicator, 2024-2034
Figure 14: Global Orphan Drugs Market Value Share Analysis, By Distribution Channel, 2023 and 2034
Figure 15: Global Orphan Drugs Market Attractiveness Analysis, By Distribution Channel, 2024-2034
Figure 16: Global Orphan Drugs Market Value Share Analysis, by Region, 2023 and 2034
Figure 17: Global Orphan Drugs Market Attractiveness Analysis, by Region, 2024-2034
Figure 18: North America Orphan Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 19: North America Orphan Drugs Market Attractiveness Analysis, by Country, 2024-2034
Figure 20: North America Orphan Drugs Market Value Share Analysis, by Country, 2023 and 2034
Figure 21: North America Orphan Drugs Market Value Share Analysis, by Disease Type, 2023 and 2034
Figure 22: North America Orphan Drugs Market Value Share Analysis, by Indicator, 2023 and 2034
Figure 23: North America Orphan Drugs Market Value Share Analysis, By Distribution Channel, 2023 and 2034
Figure 24: North America Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 25: North America Orphan Drugs Market Attractiveness Analysis, by Indicator, 2024-2034
Figure 26: Europe Orphan Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 27: Europe Orphan Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 28: Europe Orphan Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 29: Europe Orphan Drugs Market Value Share Analysis, by Disease Type, 2023 and 2034
Figure 30: Europe Orphan Drugs Market Value Share Analysis, by Indicator, 2023 and 2034
Figure 31: Europe Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 32: Europe Orphan Drugs Market Attractiveness Analysis, by Indicator, 2024-2034
Figure 33: Europe Orphan Drugs Market Attractiveness Analysis, By Distribution Channel, 2024-2034
Figure 34: Asia Pacific Orphan Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 35: Asia Pacific Orphan Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 36: Asia Pacific Orphan Drugs Market Value Share Analysis, by Disease Type, 2023 and 2034
Figure 37: Asia Pacific Orphan Drugs Market Value Share Analysis, by Indicator, 2023 and 2034
Figure 38: Asia Pacific Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 39: Asia Pacific Orphan Drugs Market Attractiveness Analysis, by Indicator, 2024-2034
Figure 40: Latin America Orphan Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 41: Latin America Orphan Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 42: Latin America Orphan Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 43: Latin America Orphan Drugs Market Value Share Analysis, by Disease Type, 2023 and 2034
Figure 44: Latin America Orphan Drugs Market Value Share Analysis, by Indicator, 2023 and 2034
Figure 45: Latin America Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 46: Latin America Orphan Drugs Market Attractiveness Analysis, by Indicator, 2024-2034
Figure 47: Middle East & Africa Orphan Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 48: Middle East & Africa Orphan Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 49: Middle East & Africa Orphan Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 50: Middle East & Africa Orphan Drugs Market Value Share Analysis, by Disease Type, 2023 and 2034
Figure 51: Middle East & Africa Orphan Drugs Market Value Share Analysis, by Indicator, 2023 and 2034
Figure 52: Middle East & Africa Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 53: Middle East & Africa Orphan Drugs Market Attractiveness Analysis, by Indicator, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Orphan Drugs Market
*86 figures and 60 tables includes